Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended): A method for the treatment of ~~of~~ a postlesional neuronal disease ~~diseases of~~ due to ischemia ~~ischemic,~~ or traumatic impact ~~or toxic origin~~, which is characterized by nerve cell necrosis, comprising administering an effective amount of a compound of formula (I) to a human patient in need thereof:



(I)

wherein X represents NH_2, NH-C_{1-3}-alkyl, or N(C_{1-3} alkyl)$_2$;

R_1 is a residue derived from the amino acid Phe which may be optionally substituted with one or more methyl groups or one or more halogen atoms[[,]]; or is a residue derived from the amino acid Ile;

R_2 is a residue derived from one of the amino acids Gly or Ile;

Y_1 and Y_2 independently from each other represent H or (C_{1-3}) alkyl;

or a pharmaceutically acceptable salt thereof.

2. (currently amended): The method according to claim 1, wherein X represents NH-C_{1-3}-alkyl, or N(C_{1-3} alkyl)$_2$.

3. (canceled)

4. (canceled)

5. (Previously Presented): The method according to claim 1, wherein R_1 is a residue derived from the amino acid Phe which may optionally be substituted with one or more methyl groups or one or more halogen atoms.

6. (Previously Presented): The method according to claim 5 wherein R_1 is a residue which is derived from Phe, which may optionally be substituted with one or more halogen atoms.

7. (Previously Presented): The method according to claim 1, wherein R_2 is a residue which is derived from the amino acid Gly.

8. (Previously presented) The method according to claim 1, wherein the compound of formula (I) is glycyl-L-phenylalanyl-L-prolineamide, N,N-diethyl-isoleucyl-phenylalanyl-L-proline ethylamide, N,N-diethyl-isoleucyl-isoleucyl-prolineamide or a pharmaceutically acceptable salt thereof.